Bita Fakhri1, Mark A Fiala2, Nina Shah1, Ravi Vij2, Tanya M Wildes2. 1. Division of Hematology and Blood and Marrow Transplantation, University of California at San Francisco, San Francisco, California. 2. Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
Abstract
BACKGROUND: Carfilzomib improves survival in patients with recurrent myeloma. Given the strict eligibility criteria in clinical trials, the actual frequency of cardiac adverse events (CAEs) and pulmonary adverse events (PAEs) and the risk factors associated with these AEs in the general population need to be established. METHODS: The authors extracted myeloma cases in the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database from 2000 through 2013 and corresponding claims through 2014. They then identified patients who received carfilzomib during their disease course. Subsequently, the International Classification of Diseases, Ninth Revision (ICD-9) was used to identify all the codes for CAEs, PAEs, and respiratory infections associated with carfilzomib use. Preexisting diagnoses corresponding to the CAEs and PAEs of interest were excluded to distinguish toxicity from comorbidity. Multivariate Cox regression was performed to determine those variables independently associated with the development of CAEs and PAEs. RESULTS: Of the 635 patients analyzed, the median age was 72 years (range, 36-94 years); 55% of the patients were male and 79% were white. The median duration of carfilzomib treatment was 58 days (range, 1-716 days). Overall, approximately 66% of the patients had codes for either CAEs or PAEs. In terms of CAEs, approximately 22% of patients developed hypertension, 15% developed peripheral edema, and 14% experienced heart failure. With regard to PAEs, approximately 28% of patients developed dyspnea, 15% developed cough, and 15% developed pneumonia. Only chronic obstructive pulmonary disease (COPD) was found to be independently associated with the development of CAEs. Patients with preexisting COPD were found to have a 40% increase in their hazard of developing CAEs (adjusted hazard ratio, 1.40; 95% CI, 1.03-1.90). CONCLUSIONS: In older adults with myeloma who are undergoing treatment with carfilzomib, new cardiac and pulmonary diagnoses were common. Patients with preexisting COPD were found to be at an increased risk of developing CAEs.
BACKGROUND:Carfilzomib improves survival in patients with recurrent myeloma. Given the strict eligibility criteria in clinical trials, the actual frequency of cardiac adverse events (CAEs) and pulmonary adverse events (PAEs) and the risk factors associated with these AEs in the general population need to be established. METHODS: The authors extracted myeloma cases in the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database from 2000 through 2013 and corresponding claims through 2014. They then identified patients who received carfilzomib during their disease course. Subsequently, the International Classification of Diseases, Ninth Revision (ICD-9) was used to identify all the codes for CAEs, PAEs, and respiratory infections associated with carfilzomib use. Preexisting diagnoses corresponding to the CAEs and PAEs of interest were excluded to distinguish toxicity from comorbidity. Multivariate Cox regression was performed to determine those variables independently associated with the development of CAEs and PAEs. RESULTS: Of the 635 patients analyzed, the median age was 72 years (range, 36-94 years); 55% of the patients were male and 79% were white. The median duration of carfilzomib treatment was 58 days (range, 1-716 days). Overall, approximately 66% of the patients had codes for either CAEs or PAEs. In terms of CAEs, approximately 22% of patients developed hypertension, 15% developed peripheral edema, and 14% experienced heart failure. With regard to PAEs, approximately 28% of patients developed dyspnea, 15% developed cough, and 15% developed pneumonia. Only chronic obstructive pulmonary disease (COPD) was found to be independently associated with the development of CAEs. Patients with preexisting COPD were found to have a 40% increase in their hazard of developing CAEs (adjusted hazard ratio, 1.40; 95% CI, 1.03-1.90). CONCLUSIONS: In older adults with myeloma who are undergoing treatment with carfilzomib, new cardiac and pulmonary diagnoses were common. Patients with preexisting COPD were found to be at an increased risk of developing CAEs.
Authors: Torben Plesner; Hendrik-Tobias Arkenau; Francesca Gay; Monique C Minnema; Mario Boccadoro; Philippe Moreau; Jamie Cavenagh; Aurore Perrot; Jacob P Laubach; Jakub Krejcik; Tahamtan Ahmadi; Carla de Boer; Diana Chen; Christopher Chiu; Jordan M Schecter; Paul G Richardson Journal: Br J Haematol Date: 2019-03-31 Impact factor: 6.998
Authors: Philippe Moreau; Maria-Victoria Mateos; James R Berenson; Katja Weisel; Antonio Lazzaro; Kevin Song; Meletios A Dimopoulos; Mei Huang; Anita Zahlten-Kumeli; A Keith Stewart Journal: Lancet Oncol Date: 2018-06-01 Impact factor: 41.316
Authors: Ajai Chari; A Keith Stewart; Stuart D Russell; Philippe Moreau; Joerg Herrmann; Jose Banchs; Roman Hajek; John Groarke; Alexander R Lyon; George N Batty; Sunhee Ro; Mei Huang; Karim S Iskander; Daniel Lenihan Journal: Blood Adv Date: 2018-07-10
Authors: Tania Jain; Hemalatha Narayanasamy; Joseph Mikhael; Craig B Reeder; P Leif Bergsagel; Angela Mayo; A Keith Stewart; Farouk Mookadam; Rafael Fonseca Journal: Blood Cancer J Date: 2017-12-13 Impact factor: 11.037
Authors: Nathanael R Fillmore; Clark DuMontier; Cenk Yildirim; Jennifer La; Mara M Epstein; David Cheng; Diana Cirstea; Sarvari Yellapragada; Gregory A Abel; J Michael Gaziano; Nhan Do; Mary Brophy; Dae H Kim; Nikhil C Munshi; Jane A Driver Journal: J Natl Cancer Inst Date: 2021-08-02 Impact factor: 13.506
Authors: Giulia Mingrone; Anna Astarita; Lorenzo Airale; Ilaria Maffei; Marco Cesareo; Teresa Crea; Giulia Bruno; Dario Leone; Eleonora Avenatti; Cinzia Catarinella; Marco Salvini; Giusy Cetani; Francesca Gay; Sara Bringhen; Franco Veglio; Fabrizio Vallelonga; Alberto Milan Journal: Front Cardiovasc Med Date: 2021-04-21